Several new therapeutic approaches aimed at slowing the progression of PD are considered disease-modifying treatments and include anti-inflammatory agents (selnoflast, azatriopine), antioxidants, agents that stimulate mitochondrial function, agents that increase glucocerebrosidase activity (ambroxol), agents that activate the glucagon-like peptide-1 receptor (exenatide, lixisenatide, Peptron), agents that block specific kinase activity (SPARCs K0706, Inhibikases IKT148009, and Il-Yangs radotinib), agents that reduce or inhibit LRRK2 activity (BIIB122), drugs that target GI tract activity (rifaximin), and molecules that prevent -syn aggregation or disaggregation of existing complexes (prasinezumab, memantine, buntanetap)
Similarly, a decrease in MUC-19 expression was observed in the digestive acinar cells of mice flown on the US space shuttle Atlantis (STS-135)
Many of the hitherto applied inhibitors of G6PDH contain sugar phosphates or various nucleotides competing with the substrate (G6P) or cofactor (NADP + ), respectively (for review see 7 )
[PubMed: 14668333] 789
Laboratory experiments with fibroblasts have suggested that AHK-Cu may contribute to processes involved in collagen formation
